Skip to main content

Nxera Pharma

Nxera Pharma Co Ltd (formerly Sosei Heptares) is a Japanese-British multinational biopharmaceutical enterprise specializing in the discovery, research, clinical development, and global wholesale distribution of innovative small-molecule and biologic medicines, prominently featuring proprietary GPCR (G protein-coupled receptor) structure-based drug design technology (Heptares technology platform) utilized to treat neurological diseases, immunological disorders, metabolic conditions, and rare diseases across Japan, the United Kingdom, and international pharmaceutical markets. Operating advanced R&D laboratories in Cambridge, United Kingdom, and Tokyo, Japan, the company is a global leader in GPCR-targeted drug discovery. Its core business operations encompass structure-based drug design, preclinical and clinical pharmaceutical development, biopharmaceutical R&D licensing partnerships, and international wholesale distribution. Revenue is derived primarily from upfront licensing fees, R&D milestone payments, and commercial drug royalties from global pharmaceutical partners. Nxera Pharma holds a leading global market position in GPCR structure-based drug discovery and neurological therapeutics. The company is headquartered in Tokyo, Japan, and its shares trade on the Tokyo Stock Exchange (TSE Prime Market).

2 of the funds FundTelligence covers report a position in Nxera Pharma.

Legal name
Nxera Pharma Co Ltd
Sector
Health Care
Country
Japan
Funds holding it
2

Funds holding Nxera Pharma

Loading...